biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech
Nanjing Legend Biotech Co.
Nanjing Legend Biotech trial registry — 36 ClinicalTrials.gov studies with program phase, status, and indication context.
2101 Cottontail Lane, Somerset, New Jersey 08873, US HQ
2,457 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 2101 Cottontail Lane, Somerset, New Jersey 08873, US
- Employees
- 2,457
- Programs
- 36
- Drugs
- 17
- Patents
- 26
Nanjing Legend Biotech clinical trials
Registry index of 36 ClinicalTrials.gov studies linked to Nanjing Legend Biotech programs — each row shows trial ID, program name, phase, status, and indication.
Nanjing Legend Biotech trial registry — 36 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Nanjing Legend Biotech.
-
LUCAR-G79D T cells — Phase 1
Clinical update -
LUCAR-G79 T cells — Phase 1
Clinical update -
LUCAR-DKS1 NK cells — Phase 1
Clinical update -
LUCAR-B68 cells product — Phase 1
Clinical update -
LUCAR-20SP cells — Phase 1
Clinical update -
LCAR-M61S cells preparation — Unknown
Clinical update -
LCAR-G08 cells — Phase 1
Clinical update -
LCAR-BCX cells product — Phase 1
Clinical update
Trial registry
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT04094766CT.gov ↗
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Refractory B Acute Lymphoblastic Leukemia
-
CT.gov ↗ - NCT04219319CT.gov ↗
Efficacy of LCAR-T2C CAR-T cells
CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ - NCT07002112CT.gov ↗
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
Relapsed/Refractory B-cell Malignancies
-
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗